In situ hybridization and other data showed that all hepatocytes express glutathione-S-transferase (GST) Ya mRNA but that specffically pericentral cells can be induced 15-to 20-fold with 3-methylcholanthrene (3-MC). In order to identify DNA sequences involved in inducible expression (pericentral hepatocytes) and constitutive expression (all hepatocytes), the (3, 14, 24) . In addition, heightened pericentral expression is characteristic of several enzymes involved in detoxification including some P450 isoenzymes, epoxide hydrolase, and some glutathione-S-transferase (GST) isoenzymes (30, 36, 41 (34) . Following hybridization and washing, the sections were exposed on Kodak NTB-2 emulsion (typically 2 to 4 days at 4°C). After the emulsion was developed, the slides were stained with standard hematoxylin-eosin stain and examined by bright-and dark-field microscopy.
Liver cells, or hepatocytes, are thought to be part of the same cell lineage and are characterized by the coordinate cell-specific transcription of genes encoding a variety of proteins and enzymes. Many of these proteins and their mRNAs are produced equally by all hepatocytes, with albumin being a typical example (3, 35) . However, a number of proteins and their mRNAs show region-specific differences within the liver acini. For example, glutamine synthetase (GS) is expressed in adult rodents only in the immediate cell layer surrounding the central vein (3, 14, 24) . In addition, heightened pericentral expression is characteristic of several enzymes involved in detoxification including some P450 isoenzymes, epoxide hydrolase, and some glutathione-S-transferase (GST) isoenzymes (30, 36, 41) . Antibody staining reveals that some of these enzymes appear to be present in all hepatocytes at a low level. After animals are treated with xenobiotic metabolites, however, these proteins are found in high levels in the pericentral 50% of hepatocytes. In other cases, it appears that expression occurs only after induction and that expression is pericentral. Pericentral expression following induction in all cases appears by antibody staining to be sharply demarcated. Finally, some proteins and their mRNAs (for example, several enzymes of the urea cycle) are strictly localized to the periportal area. Such all-or-none positional expression for several different sets of proteins seems unlikely to be due to gradients of metabolites, as previously postulated (22) . In fact, we observed localized differentiation of the pericentral proteins major urinary protein (MUP) and GS in cultured fetal hepatocytes where no gradients for soluble metabolites exist (3) . Therefore, region-specific distribution patterns most likely represent positional regulation of gene expression within the same cell lineage due to other signals, for example, extracellular cell surface contacts.
The GSTs are a family of isoenzymes composed of homoand heterodimers of at least seven subunits. Several of these subunits are induced by xenobiotic compounds (35) . In this * Corresponding author.
article, we extend the histochemical analysis of the Ya subunit of GST to the transcriptional level. Using in situ hybridization, we demonstrate that the GST Ya mRNA is present in all hepatocytes in uninduced mice and is specifically induced by 3-methylcholanthrene (3-MC) in the pericentral region of the liver. In order to determine the genetic elements important for both basal expression (all hepatocytes) and inducible expression (pericentral hepatocytes), we dissected the upstream region of the GST Ya gene by using transient transfections in hepatoma cells and identified binding sites for proteins potentially important in both basal and inducible expression.
MATERIALS AND METHODS Cells. HepG2 cells were maintained as monolayer cultures and grown in Ham F12 medium supplemented with 5% heat-inactivated fetal calf serum (Hyclone), 0.5x minimal essential amino acids (GIBCO Laboratories), garamycin (Schering Corp.) at 25 ,ug/ml, and insulin (Eli Lilly & Co.) at 0.5 U/ml. HeLa, 293, WISH, and FS2 cells were maintained as monolayer cultures and grown in Dulbecco modified Eagle medium supplemented with 10% heat-inactivated fetal calf serum.
In situ hybridization. Liver tissues were perfused with 4% paraformaldehyde in lx PBS in situ, cut into small pieces, and then fixed overnight in 4% paraformaldehyde in 1 x PBS at 4°C. The tissue was then equilibrated overnight in 30% sucrose at 4°C and mounted in Tissue-Tek O.C.T. compound for frozen sectioning. Sections (5 ,m) were hybridized as described by Kuo et al. (24) with an antisense "S-labeled probe prepared from a T7 RNA transcript of a rat GST Ya cDNA (34) . Following hybridization and washing, the sections were exposed on Kodak NTB-2 emulsion (typically 2 to 4 days at 4°C). After the emulsion was developed, the slides were stained with standard hematoxylin-eosin stain and examined by bright-and dark-field microscopy.
GST Ya plasmid constructions and transfections. The -4.5-kilobase-pair (kbp) GST Ya construct was prepared from the GST Ya gene by the addition of a BamHI linker at the SmaI site (+66 bp) in the first intron (T. H. Rushmore, R. G. King, K. E. Paulson, and C. B. Pickett, Proc. Natl. Acad. Sci. USA, in press), followed by cleavage with EcoRI (-4.5 kbp) and BamHI. The resulting -4.6-kbp fragment containing -4.5 kbp of upstream sequence and +66 bp of downstream sequence was cloned into the adenovirus E1B expression vector (5) by standard methods (28) . The -1.55-kbp GST Ya construct was prepared from the -4.5-kbp GST Ya construct by the addition of an EcoRI linker at the XbaI site (-1.55 kbp), followed by cleavage with EcoRI and BamHI. The resulting -1.65-kbp fragment containing -1.55 kbp of upstream sequence and +66 bp of downstream sequence was cloned into the adenovirus E1B expression vector. Additional 5' and internal deletions were constructed from the -1.55-kbp construct by using advantageous restriction enzyme cleavage sites. Bal 31 exonuclease III was used to produce progressive 5' deletions starting with the -1.55-kbp GST Ya construct as described previously (5) . Digestion products were removed every 20 s for 4 min, and after termination of the reaction, the ends were repaired and EcoRI linkers were ligated (28) . The products were cleaved with EcoRI and size-separated on a 1% low-melting-point agarose gel, isolated, and cloned by standard methods (28) into the adenovirus E1B expression vector (gift of Lee E. Babiss). After transformation of Escherichia coli MC1061, clones were analyzed by restriction analysis and deletion end points were determined by DNA sequencing (37) . The GST Ya enhancer fragment from -980 bp to -650 bp was cloned into the P-globin promoter plasmid (5) at -341 bp in either orientation by using ligated HindIII linkers. The GST Ya 3-MC-inducible-site oligonucleotide (-910 bp to -875 bp) was cloned into the -190-bp deletion at the EcoRI site created by the linker.
Cultured cells were transfected at 50% confluency in Dulbecco modified Eagle medium supplemented with 10% heat-inactivated fetal calf serum, lx nonessential amino acids, and insulin at 0.5 U/ml, using the calcium phosphate coprecipitation method as described previously (5) . Expression levels of the GST Ya constructs were determined by RNase T2 digestion of hybrids between transfected RNA (20 jig) and labeled antisense RNA probes specific to the GST Ya first exon as described previously. The RNase-resistant hybrids were analyzed on 8 M urea-6% polyacrylamide gels, followed by autoradiography. An appropriate control plasmid (5) was included in the transfections to monitor transfection efficiency.
Protein-DNA-binding assays. Nuclear extracts were prepared from cultured cells as described by Dignam et al. (10) with a final NaCl concentration of 0.4 M to extract proteins from the nuclei. Nuclear extracts were prepared from fresh tissue by the method of Gorski et al. (17) . Protein-DNA binding was carried out as described by Costa et al. (6) and analyzed on a 6% polyacrylamide gel, followed by autoradiography. Methylation protection and exo III experiments. Highspecific-activity 3'-end-labeled probes were prepared as described by Costa et al. (6) . Methylation protection experiments with HepG2 nuclear extracts were also performed as described by Costa et al. (6) . The 3-MC-inducible protein-DNA interaction was footprinted by using partially purified protein (gift of A. S. Yee). In vitro exo III reactions were performed with 1 ng of a uniquely end-labeled probe (extending from -815 bp to -725 bp of the GST Ya upstream region) by the method of Kovesdi et al. (23) . For all reactions, 4 ,ug of nuclear extract was used, as was 4 ,g of poly(dI-dC) (Pharmacia, Inc.) as a nonspecific competitor of DNA-binding proteins.
RESULTS
In situ hybridization analysis of GST mRNA distribution. Immunohistochemical staining of 3-MC-treated and untreated animals shows a large increase in total GST protein in the pericentral hepatocytes of treated animals (41) . We investigated whether the changes induced by 3-MC on GST protein distribution were reflected in changes in the GST Ya mRNA distribution. A 35S-labeled antisense probe to GST Ya mRNA was used for in situ hybridization of 3-MC-treated and untreated liver sections. The GST Ya mRNA was evenly distributed throughout the liver of uninduced animals ( Fig.  1B and C) . However, a dramatic increase in mRNA was observed in 3-MC-induced animals (Fig. 1F) . Treatment with 3-MC results in a 7-to 10-fold increase in total mRNA (34) (data not shown). Because the induction is apparently restricted only to pericentral cells (approximately 50% of all hepatocytes), the true induction is 15-to 20-fold in those cells. It is noteworthy that the induction by 3-MC was not rapid. Three hours after initial treatment with 3-MC, there was a marginal change in GST mRNA distribution ( Fig. 1D and E). Only after 48 h and multiple 3-MC injections was the full pattern of induction observed (Fig. 1F) . Similar kinetics were observed for total GST mRNA induction (data not shown). Whether this is due to the low solubility of 3-MC and the consequent slow delivery to the liver is not clear, but as demonstrated later, cultured cells responded more quickly.
As a control for the specificity of the in situ hybridization, an antisense RNA probe for the generally distributed transthyretin (TTR) protein was used. TTR probe gave a uniform distribution in liver sections, as expected (data not shown). In addition, an RNA probe for MUP was used as a control for pericentral expression. MUP is a constitutively expressed, predominantly pericentral protein (3), and this was also reflected in the mRNA distribution pattern (Fig. 1A) .
Localization of GST Ya gene regulatory elements in HepG2 (human hepatoma) cells. In a preliminary analysis of the GST Ya upstream region, deletion from -4.5 kbp to -1.6 kbp did not affect the basal or xenobiotic compound-inducible expression of RNA from plasmid constructs transfected into a variety of hepatoma cell lines, whereas a deletion of -650 bp had no basal or inducible activity (39) . Further, deletion analysis (Rushmore et al., in press) located DNA segments in the -650 bp to -750 bp region that are responsible for either induced or basal expression of the Ya mRNA. To determine the possible importance of other DNA segments upstream of -750 bp and to characterize the exact binding sites and cognate proteins, another series of deletions between -1.55 kbp and -650 bp were prepared. Transfection of these deletion mutants into HepG2 cells was carried out to test for both basal and 3-MC-inducible activity. In all experiments, a control plasmid containing a simian virus 40 (SV40) enhancer/,-globin promoter minigene was cotransfected to quantitate transfection efficiency (5). A 5' deletion to -980 bp retained full basal activity and 3-MC-inducible activity ( Analysis of enhancer activity of -980 bp to -650 bp. Although the 5' deletion data indicated that the sequences from -980 bp to -650 bp were required for full activity of the GST Ya gene, it was unclear whether additional sequences between -650 and the promoter were also required. Therefore, the -980 bp to -650 bp segment was moved next to the promoter-proximal region at -190 bp and cloned in either orientation. The -980 bp to -650 bp segment made the promoter beginning at -190 bp fully active and inducible ( Fig. 2A) . Therefore, it is unlikely that any sequences between -650 bp and -190 bp are required for complete enhancer activity. A further test of enhancer activity was to determine whether -980 bp to -650 bp was capable of activating a heterologous promoter. Therefore, the GST Ya enhancer was cloned in either orientation 5' to a 13-globin promoter minigene construct (5). The GST enhancer was able to activate the 1-globin promoter three-to fivefold in untreated HepG2 cells and 10-to 20-fold in the presence of (Fig. 3) . This is approximately the same degree of stimulation by 3-MC that was observed in the natural gene.
Cell specificity of the GST Ya enhancer and promoter. The tissue distribution of GST Ya expression in rats is predominantly in hepatocytes and to a lesser extent in kidney cells (25) Fig. 5A and quantitated by densitometry (data not shown), the -1.55-kbp construct was maximally induced between 4 and 8 h of 3-MC treatment. However, it is evident that even by 2 h of treatment, mRNA from the transfected DNA had increased significantly. Therefore, because 3-MC induction in HepG2 cells was rapid, we prepared nuclear extracts from both short and long 3-MC treatment times. Protein-DNA binding was tested by electrophoretic mobility shift assays, in which protein-DNA complexes are resolved from unbound labeled DNA. One or more proteins specifically bound to the DNA probe (-980 bp to -875 bp) in both 3-MC-treated and untreated extracts (Fig. 5B) To locate precisely the DNA-binding site for the induced protein factor, dimethylsulfate (DMS)-methylation protection footprints were performed on the induced protein-DNA complexes. Protected G residues were found on both the upper and lower strands between -905 bp and -885 bp, that is, within the region identified as necessary in the functional analysis (-925 bp to -875 bp) (Fig. 5C) . Finally, to test the functionality of this protected sequence, we prepared a double-stranded oligonucleotide which encompassed -910 bp to -875 bp and cloned it in front of the GST Ya promoter at -190 bp. As shown in Fig. SD , the promoter plus the -910 bp to -875 bp oligonucleotide was induced by 3-MC, while the construct without the upstream element was not. Furthermore, as expected, the -910 bp to -875 bp oligonucle- Nuclear protein binding in the basal expression region -875 bp to -650 bp. As described earlier (Fig. 2) tein-DNA complexes. Labeled DNA probe from -875 bp to -815 bp was bound by nuclear extract whether or not the cells had been treated with 3-MC (Fig. 6A) . A specific band that could be competed with by unlabeled oligonucleotide containing a binding site for the constitutive hepatocytespecific factor HNF1 (7) was present whether or not 3-MC treatment was used. Identification of this putative HNF1 site was confirmed by the DMS-methylation protection footprint of the protein-DNA complex (Fig. 6B) . Protected A residues (there are no G's in this sequence) were encompassed by the region from -860 bp to -850 bp, which matches the HNF1 consensus in 10 of 12 bases. HNF1 is known to be a positive-active factor, and the deletion of this site decreased HepG2 expression of the GST construct about twofold (Fig.  2) . In addition, deletion of HNF1 sites from several other liver-specific enhancers resulted in similar or even smaller but reproducible reductions in enhancer activity in HepG2 cells (6, 18) .
Although a construct with -815 bp of upstream sequence still had some basal activity in transfection assays, further 5' deletions within the -815 bp to -650 bp region abolished all activity (Fig. 2) . Therefore, these sequences were tested for protein-DNA interactions. As shown in Fig. 7A , a labeled DNA probe covering -810 bp to -720 bp produced a gel shift band that was competed with by cold homologous DNA as well as an oligonucleotide containing the binding site to the hepatocyte-enriched factor HNF4 (6). An exo III assay was used to probe the boundary of this protein-DNA interaction. The probe used in this experiment was slightly different from that described in the legend to Fig. 7A and encompassed -815 bp to -705 bp. As shown in Fig. 7B , exo III stops which were specifically competed with by unlabeled homologous DNA and the HNF4 oligonucleotide defined the site as -775 bp to -755 bp. Within this exo IIIprotected region were sequences which aligned closely with a consensus sequence for the HNF4 site (Fig. 7B ) (F. Sladek, unpublished results). In addition, the cell type distribution of the protein binding to -775 to -755 bp was the same as HNF4 (data not shown). Therefore, we conclude that an HNF4-like factor interacts at -775 bp to -755 bp.
When a DNA probe from -725 bp to -650 bp was used in a gel shift assay, a specifically competable band was also apparent (Fig. 8A) . This complex was competed with by a fragment from the albumin enhancer, which is bound by a positive-acting protein, termed NLS (20) . The NLS factor, which binds a positive-acting site in the albumin enhancer, is not cell specific in its distribution, and similarly, the distribution of the protein that formed complexes on the -725 bp to -650 bp probe was also present in several cell types (data not shown). The possible identity of the NLS factor and the GST Ya-binding protein was examined by cross-competition (Fig. 8A) . Both the unlabeled NLS fragment from the albumin enhancer and unlabeled -725 bp to -650 bp fragment were able to compete with a gel shift band produced by a partly purified NLS factor. The location of the NLS-like DNA-binding site was determined by DMS-methylation proMethylation interference was performed by premethylating the -875 bp to -815 bp fragment (29) , followed by a scaled-up binding reaction and analysis as described in the legend to Fig. 5 . The brackets indicate the protected or interfering residues (all A's). F indicates free, unbound probe, and B indicates bound probe. Below the gels are a comparison of the consensus HNF1 site (7) and the protected sequence in the GST Ya enhancer. + indicates fully protected residues, and o indicates partially protected residues. (12, 16, 21, 32, 38) . Based on DNA sequence homologies within these regions, a consensus xenobiotic-responsive element (XRE) or dioxin-responsive element (DRE) has been identified (9, 13) . The sequence of the footprinted region of the GST Ya gene contains a sequence that resembles the so-called XREs or DREs. gene has several similarities to the various steroid receptorbinding sites, including an inverted repeat in the contact region (with one-base-pair mismatch, as indicated in the diagram). This characteristic was not described for XREs but is expected of a binding protein that belongs to the steroid receptor superfamily (11) . Further mutagenesis studies are required to determine which bases are most important for induced protein binding and function.
The identity of the observed 3-MC-inducible protein is unknown at present. However, the kinetics of 3-MC induction of the GST Ya protein-DNA complex are very similar to those of the xenobiotic receptor or dioxin receptor, which has been postulated to be a member of the steroid hormone receptor superfamily (9, 19) . Only 1 h of exposure to dioxin is required for maximal induction of a protein that binds a DRE. In addition, this binding activity is greatly diminished at 4.5 h of exposure and is completely gone by 16 h (19) . It should also be noted that the study of Telakowski-Hopkins et al. (39) showed that the GST Ya gene is not responsive when transfected into cells lacking this dioxin receptor. Finally, we found that cycloheximide had no effect on 3-MC induction of the GST Ya gene (data not shown), indicating that the 3-MC-induced protein-DNA interaction may be due to a preexisting xenobiotic receptor. From the in situ hybridization results and the identification of the 3-MC-inducible site as an XRE, it might be possible that the xenobiotic compound receptor is represented only in pericentral hepatocytes.
As shown in Fig. 5 through a common sequence element (40) . Also, the thyroid hormone receptor appears to act as an antagonist to estrogen receptor binding at the same site and consequently blocks transcriptional induction by estrogen (15) . We In addition to the putatively pericentral location of the induced protein factor, we also identified several nuclear factors from hepatocytes that interact with the basal or constitutive part of the GST Ya enhancer. A summary of all protein-DNA interactions in the GST Ya enhancer is shown in Fig. 9 . The basal enhancer consists of at least three protein-DNA interactions, including hepatocyte-enriched factors similar or identical to HNF1 and HNF4 and a non-tissue-specific NLS-like factor. Because none of the purified factors have been shown to interact with the identified sites, we cannot be conclusive about the identity of the factors. All of the sites identified are important for full enhancer function in hepatoma cells. We have not assessed the role of these sites in other cell types, although the enhancer can function at a low level in some nonhepatoma lines. Perhaps this reflects the role of the NLS-like site, or perhaps there are additional as yet unidentified protein-DNA interactions which mediate enhancer activity. Interestingly, the arrangement of liver-specific and constitutive factor binding sites seems to be a general feature of several liverspecific enhancers and promoters studied so far (2, 4, 6, 18, 26, 27) . The GST Ya enhancer also fits this pattern in its arrangement of binding proteins.
Having identified the critical sequences and protein-binding sites for both basal and 3-MC-inducible expression of the GST Ya gene, we are assessing the role of these sequences in vivo. We are producing transgenic mice to examine the role of upstream GST Ya sequences on inducible pericentral expression in vivo and the role of the constitutive elements in general expression. Our detailed understanding of the molecular interactions in the GST Ya enhancer and the use of transgenic mice should allow us to follow the developmental decisions which occur during hepatocyte positional differentiation.
